RICHMOND – Troutman Pepper Locke represented Blue Heron Capital, an early-stage growth equity firm, in its investment in Remission Medical, Inc. (Remission Medical) a virtual rheumatology company that contracts directly with health systems to deliver embedded specialty care. For more information, see the press release.
The investment will fuel expansion of Remission Medical’s partner network, grow its clinical workforce, and accelerate the scaling infrastructure that allows Remission Medical to rapidly deploy rheumatology access across more systems, more markets, and ultimately more specialties.
The team that represented Blue Heron Capital was led by Dan Sieck, Mike McCann, and DJ Griffin.
Consistently recognized as a top-tier practice, Troutman Pepper Locke’s Private Equity and Investment Funds Group regularly handles middle market transactions for private equity clients alongside strategic deals for Fortune 100 corporations. Core areas of service include mergers and acquisitions, corporate finance, corporate governance, securities laws compliance, capital markets transactions, and other significant domestic and cross-border transactions, as well as general corporate counseling. The firm has a strong focus in the private equity and private fund services space, advising clients on matters including fund formation, growth equity investments, leveraged buyouts, recapitalizations, and exit transactions.
Troutman Pepper Locke
Troutman Pepper Locke helps clients solve complex legal challenges and achieve their business goals in an ever-changing global economy. With more than 1,600 attorneys in 30+ offices, the firm serves clients in all major industry sectors, with particular depth in energy, financial services, health care and life sciences, insurance and reinsurance, private equity, and real estate. Learn more at troutman.com.